NCT02833610: Phase 2 - A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

NCT02833610: Phase 2 - A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency.

Sponsor:

Massachusetts General Hospital

Collaborators:

Amgen

Emory University

University of Rochester

University Hospitals Cleveland Medical Center

Multiple locations

ClinicalTrials.gov Identifier: NCT02833610

Official Title: A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

https://clinicaltrials.gov/ct2/show/NCT02833610

---

Denosumab: National Cancer Institute

Denosumab: MedlinePlus Drug Information

---

Drug: Denosumab Q4W